FOLD$14.31
Chart
Performance
Key Stats
AI FOLD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralAmicus Therapeutics shows mixed signals, with a solid fundamental base and positive short-term performance but facing headwinds in long-term profitability and potential regulatory concerns. Technicals are mixed across different timeframes.
Thematic
Amicus Therapeutics operates in the rare disease space, which has favorable long-term demographic trends. However, specific thematic tailwinds are not as pronounced as in broader tech sectors.
Fundamental
The company demonstrates revenue growth and improved profitability in the latest periods. However, historical net losses and the current negative EPS estimates suggest profitability is still developing.
Technical
Short-term technical indicators show a bullish trend, with prices above key moving averages. However, some oscillators suggest the stock may be approaching overbought conditions on certain timeframes.
| Factor | Score |
|---|---|
| Rare Disease Market Growth | 70 |
| Biotechnology Innovation | 65 |
| Competitive Landscape | 50 |
| Regulatory Environment | 55 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 75 |
| Growth | 80 |
| Balance Sheet Health | 40 |
| Cash Flow | 45 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Attractive Valuation
The Price/Sales (P/S) ratio of 4.9 for 2023 is lower than the previous year's 6.0, suggesting improved valuation efficiency.
Positive EPS Surprise
Recent quarterly EPS surprises have been positive, with Q1 2025 showing a 246.26% surprise, indicating better-than-expected earnings performance.
Bearish Points (8)
Negative Net Income and Margins
The company reported a net loss of $56,106,000 in 2024 with a net margin of -10.6%, indicating unprofitability.
Margin Compression
Net margin has worsened from -10.6% in 2024 to -38.0% in 2023, indicating declining profitability efficiency.
Calendar
July 2025
31
Next Earnings Date
H: $0.07
A: $0.02
L: $-0.03
H: 157.60M
A: 146.68M
L: 137.15M
Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Seasonals
Price Target
15.82 USD
The 39 analysts offering 1 year price forecasts for FOLD have a max estimate of 22.00 and a min estimate of 9.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Provides a physics-based computational platform essential for drug discovery, including modeling protein structure, dynamics, and ligand binding, directly influencing understanding of protein folding.
Weight: 93
Leverages AI and machine learning to map complex biological systems and accelerate drug discovery, often involving the understanding of protein interactions and cellular pathways related to disease mechanisms.
Weight: 92
Focuses on 'protein motion' and conformational changes as a key to drug discovery, exploring the dynamic aspects of protein folding and how drugs interact with these flexible structures.
Weight: 90
A global leader in developing treatments for Cystic Fibrosis, a genetic disease fundamentally caused by the misfolding of the CFTR protein.